Mitigate risks for clinicians and patients    

Expert-backed testing to monitor therapy, assess risk, and identify misuse

Controlled substances are widely prescribed for a number of clinical indications; however, these substances have a high risk for misuse and diversion. To help clinicians manage the challenges of abuse presented by controlled substances, the American Association for Clinical Chemistry Academy developed Laboratory Medicine Practice Guidelines that recommend using clinical laboratory tests to monitor drug therapy in pain management patients.

The Clinical and Forensic Toxicology Laboratory at Mayo Clinic offers the industry’s most comprehensive evidence-based urine drug testing menu. Our profiles were developed with consistency to practice guidelines and help clinicians identify specific prescription drugs, adulterants, and illicit substances. Our screening and monitoring assays employ a variety of methodologies that capitalize on emerging technologies to offer the highest level of testing across the spectrum of controlled substances for precision insights on patients’ drug use.

Pain management is among the most common legitimate uses for controlled substance therapy. Our streamlined approach to controlled substance monitoring ensures accurate results through validity testing and interpretive reports. Learn more about Mayo Clinic Laboratories’ Pain Management testing services.

Drug testing evaluations

Comprehensive drug profiles

Targeted screening

Confirmatory testing

Chain of custody

Result interpretations

Specific drug groups

Benzodiazepines

Ethanol

Opioids

Marijuana (THC-COOH)

Stimulants & PCP

By the numbers

50%

combining clinical UDT with other risk-mitigation strategies can reduce substance misuse by at least 50%1

10.1

million people misused prescriptions in 20192

38

people died every day from overdose, including opioids3

Our comprehensive profiles

Routine monitoring

CSMPU  | Controlled Substance Monitoring Profile, 20 Drug Classes, Urine

  • Identifies drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine (PCP) and carboxy-tetrahydrocannabinol (COOH-THC)
  • Includes specimen validity testing
  • Results reported with interpretative comments

Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU)

Comprehensive monitoring

CSMEU  | Controlled Substance Monitoring Enhanced Profile, 21 Drug Classes, Urine

  • Identifies drug use involving alcohol**, amphetamines, barbiturates, benzodiazepines, cocaine, opioids, PCP, and COOH-THC
  • Includes specimen validity testing
  • Results reported with interpretative comments

Our targeted screening profiles

Targeted screening

CSMTU  | Controlled Substance Monitoring Targeted Profile, 17 Drug Classes, Urine

  • Identifies drug use involving amphetamines, benzodiazepines, opioids, and PCP where immunoassays are not adequate
  • Includes specimen validity testing
  • Results reported with interpretative comments

TOSU  | Targeted Opioid Screen, 10 Drug Classes, Urine

  • Uses high-resolution accurate mass spectrometry to identify 33 different opioids and metabolites (i.e.,buprenorphine, codeine, fentanyl, heroin, hydrocodone, hydromorphone, methadone, morphine, naloxone, oxycodone, tapentadol, tramadol) where immunoassays are not adequate
  • Detects spiked specimens
  • Results reported with interpretative comments
  • Learn more about Opioid Monitoring

TBSU  | Targeted Benzodiazepine Screen, 3 Drug Classes, Urine

  • Uses high-resolution accurate mass spectrometry to identify 27 different benzodiazepines and metabolites (i.e., clobazam, zolpidem and all commonly prescribed benzodiazepines) where immunoassays are not adequate
  • Detects spiked specimens
  • Results reported with interpretative comments
  • Learn more about Benzodiazepine Monitoring

TSPU  | Targeted Stimulant Screen, 4 Drug Classes, Urine

  • Uses high-resolution accurate mass spectrometry to identify 11 different stimulants and metabolites (i.e., amphetamines, methylphenidate, ritlanic acid, 3,4-Methylenedioxymethamphetamine [MDMA], PCP) where immunoassays are not adequate
  • Detects spiked specimens
  • Results reported with interpretative comments
  • Learn more about Stimulant Monitoring

*To better meet the needs of our clients’, this profile is available with the quantification of presumptive positive results (Mayo Test ID: CSMPU) or without (Mayo Test ID: CSMHU) for the drug classes screened by immunoassay (i.e., barbiturates, cocaine, and THC).
**Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are direct biomarkers of ethanol and are detectable in urine for up to five days following alcohol consumption. EtG/EtS results should be interpreted in the context of all available clinical and behavioral information.

References

  1. Argoff CE, Kahan M, Sellers EM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. J Opioid Manag. 2014;10(2):119–134.
  2. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health
  3. U.S. Food & Drug Administration: Online Opioid Summits

Learn more about how to order these tests at your institution.

Resources

Visit Mayo Clinic Laboratories at the APA Annual Meeting
May 15, 2023

Visit Mayo Clinic Laboratories at booth #2047 to learn about our comprehensive therapeutics test offerings. Developed by board-certified experts in clinical chemistry, molecular, and toxicology testing, our testing is designed to detect and monitor therapeutic and illicit drugs across several relevant specimen types.
Register today for the APA Annual Meeting 2023
May 8, 2023

Join us for the APA Annual Meeting 2023, the premier event for psychiatrists and mental health professionals. This year's meeting will be held May 20–24 in San Francisco and will feature an exciting program of educational sessions, expert speakers, and networking opportunities.
Interpretation of qualitative and quantitative urine opiate tests for pain management patients
May 3, 2021

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the use of qualitative urine screening assays and quantitative confirmatory testing to determine compliance in pain management patients.
High-resolution targeted stimulant and phencyclidine (PCP) screen
April 5, 2021

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted stimulant and PCP screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed CNS stimulant medications.
Improving outcomes through comprehensive controlled substance monitoring
March 10, 2021

Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new comprehensive Controlled Substance Monitoring Panel, developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic Laboratories, offers in-depth analysis on more than 70 different prescription medications and illicit substances to provide clinicians with details and interpretations on patients’ controlled substance use lacking in other laboratory assays.
New High-Resolution Targeted Opioid Screen: Superior Sensitivity and Specificity to Evaluate Adherence to Prescribed Opioid Therapy
July 13, 2020

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted opioid screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed opioid pain-relieving medication.